A Study to Assess the Ability of Eltrombopag to Induce Sustained Response Off Treatment in Subjects With ITP

Phase 2 Completed 105 enrolled Novartis Pharmaceuticals

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this trial was to assess the ability of eltrombopag to induce sustained treatment-free remission in immune thrombocytopenia purpura (ITP) subjects who relapsed or failed to respond to an initial treatment with steroids.

Timeline

Start: 2018-11-02
Primary completion: 2021-10-22
Completion: 2022-10-03

Publications

Cooper N, Ghanima W, Vianelli N, Valcarcel D, Yavasoglu I, Melikyan A, Ruiz EY, Haenig J, Somenzi O, Lee J, Clark J, Zhang Y, Zaja F. Sustained response off-treatment in eltrombopag-treated adult patients with ITP who are refractory or relapsed after first-line steroids: Primary, final, and ad-hoc analyses of the Phase II TAPER trial. Am J Hematol. 2024 Jan;99(1):57-67. doi: 10.1002/ajh.27131. Epub 2023 Nov 28.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Eltrombopag	Small molecule	12.5 mg	Oral
Subject	Eltrombopag	Small molecule	25 mg	Oral
Subject	Eltrombopag	Small molecule	50 mg	Oral
Subject	Eltrombopag	Small molecule	75 mg	Oral

A Study to Assess the Ability of Eltrombopag to Induce Sustained Response Off Treatment in Subjects With ITP

Summary

Timeline

Publications

Drugs

Indications